IN2014KN02672A - - Google Patents

Info

Publication number
IN2014KN02672A
IN2014KN02672A IN2672KON2014A IN2014KN02672A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A IN 2672KON2014 A IN2672KON2014 A IN 2672KON2014A IN 2014KN02672 A IN2014KN02672 A IN 2014KN02672A
Authority
IN
India
Prior art keywords
mammal
csf
ependymal cells
apoe
protective
Prior art date
Application number
Other languages
English (en)
Inventor
Beverly L Davidson
Bradley T Hyman
Original Assignee
Univ Iowa Res Found
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found, Gen Hospital Corp filed Critical Univ Iowa Res Found
Publication of IN2014KN02672A publication Critical patent/IN2014KN02672A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN2672KON2014 2012-05-18 2013-03-14 IN2014KN02672A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648801P 2012-05-18 2012-05-18
PCT/US2013/031725 WO2013172964A1 (en) 2012-05-18 2013-03-14 Methods and compositions for treating amyloid deposits

Publications (1)

Publication Number Publication Date
IN2014KN02672A true IN2014KN02672A (enExample) 2015-05-08

Family

ID=49584137

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2672KON2014 IN2014KN02672A (enExample) 2012-05-18 2013-03-14

Country Status (12)

Country Link
US (1) US20150183850A1 (enExample)
EP (1) EP2850195B1 (enExample)
JP (2) JP6469000B2 (enExample)
CN (2) CN112574964A (enExample)
AU (1) AU2013263346B2 (enExample)
BR (1) BR112014028666B1 (enExample)
CA (1) CA2873890C (enExample)
ES (1) ES2786078T3 (enExample)
HK (1) HK1207109A1 (enExample)
IN (1) IN2014KN02672A (enExample)
RU (1) RU2673484C2 (enExample)
WO (1) WO2013172964A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975583A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2016196507A1 (en) 2015-05-29 2016-12-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
US20180161395A1 (en) * 2015-06-12 2018-06-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
JP7161401B2 (ja) * 2016-04-14 2022-10-26 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド(aspd)様構造体及び医薬組成物
IL262784B2 (en) 2016-05-18 2023-10-01 Voyager Therapeutics Inc modulatory polynucleotides
NZ750291A (en) * 2016-08-03 2021-07-30 Univ South Florida Reelin compositions for treatment of neurological disorders
CN110121356A (zh) * 2016-09-02 2019-08-13 星火治疗股份有限公司 治疗cns疾病的方法和载体
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス,インコーポレーテッド ライソゾーム病の遺伝子治療
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
JP7616995B2 (ja) * 2018-11-28 2025-01-17 プリベイル セラピューティクス,インコーポレーテッド 神経変性疾患のための遺伝子治療
MX2022004524A (es) * 2019-10-16 2022-07-21 Univ Cornell Tratamiento génico para la enfermedad de alzheimer.
KR20230020946A (ko) * 2020-03-31 2023-02-13 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. 중수소화 옥소페닐아르신 화합물 및 이의 용도
CN116670291A (zh) * 2020-11-25 2023-08-29 普利维尔治疗公司 用于神经退行性疾病的基因疗法
US20250297279A1 (en) * 2021-12-15 2025-09-25 Genans Biotechnology Co., Ltd Recombinant aav vectors and use thereof
CN116063405B (zh) * 2022-09-27 2025-08-29 广州译码基因科技有限公司 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
NZ555830A (en) * 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
DK1879623T3 (da) * 2005-05-02 2012-12-17 Genzyme Corp Genterapi til rygmarvssygdomme
WO2008033375A2 (en) * 2006-09-14 2008-03-20 Medgenics Ltd. Long lasting drug formulations
HUE027278T2 (en) * 2007-05-16 2016-11-28 Brigham & Womens Hospital Inc Treatment of synucleinopathies
CA2833912C (en) * 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders

Also Published As

Publication number Publication date
EP2850195A4 (en) 2015-12-09
JP6469000B2 (ja) 2019-02-13
EP2850195A1 (en) 2015-03-25
CN112574964A (zh) 2021-03-30
RU2673484C2 (ru) 2018-11-27
CA2873890C (en) 2022-12-06
HK1207109A1 (en) 2016-01-22
JP2019031564A (ja) 2019-02-28
RU2014151218A (ru) 2016-07-10
BR112014028666B1 (pt) 2021-12-07
CA2873890A1 (en) 2013-11-21
EP2850195B1 (en) 2020-01-22
AU2013263346B2 (en) 2018-08-23
ES2786078T3 (es) 2020-10-08
US20150183850A1 (en) 2015-07-02
CN104540952A (zh) 2015-04-22
WO2013172964A1 (en) 2013-11-21
JP2015520161A (ja) 2015-07-16
BR112014028666A2 (pt) 2017-06-27
AU2013263346A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
IN2014KN02672A (enExample)
CA2832151C (en) Methods and compositions for treating brain diseases
MX2023007728A (es) Composiciones para el tratamiento de esclerosis lateral amiotrofica (ela).
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
WO2015013148A3 (en) Methods and compositions for treating brain diseases
PH12017501436A1 (en) Enhanced delivery of viral particles to the striatum and cortex
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
WO2015109124A3 (en) Immunomodulatory agents
PH12018501055A1 (en) Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
MX2015014423A (es) Administración efectiva de genes grandes por vectores aav duales.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
TN2014000438A1 (en) Anti-fcrn antibodies
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX2015016814A (es) Anticuerpo anti-tweakr y sus usos.
MX351154B (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2014015002A (es) Polipeptidos que tienen actividad de transgalactosilacion.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
Dubsky et al. Category O for the Schrödinger algebra
MX2019005266A (es) Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas.
MX353911B (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014058866A3 (en) Treatment of amyotrophic lateral sclerosis
WO2014195356A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2013163590A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144